R

Royalty Pharma plc
D

RPRX

26.410
USD
0.02
(0.08%)
Market Closed
Volume
78,928
EPS
2
Div Yield
3.18
P/E
10
Market Cap
11,734,006,867
OverviewSignalsIdeasNews
Related Instruments
    A
    AKBA
    -0.07500
    (-4.02%)
    1.79000 USD
    B
    BLCM
    -0.01620
    (-4.09%)
    0.36000 USD
    C
    CRBP
    -0.950
    (-5.41%)
    16.610 USD
    E
    ETON
    -0.407
    (-3.89%)
    10.060 USD
    G
    GLYC
    0.02000
    (4.95%)
    0.42420 USD
    K
    KPTI
    -0.02960
    (-3.54%)
    0.80740 USD
    V
    VKTX
    -3.960
    (-7.39%)
    49.620 USD
    V
    VNDA
    -0.09500
    (-1.87%)
    4.99500 USD
    X
    XNCR
    -0.420
    (-1.79%)
    23.090 USD
    More
News

Title: Royalty Pharma plc

Sector: Healthcare
Industry: Biotechnology
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.